Spero Therapeutics just reported Q1 2026 results after the close on May 13, and the headline numbers tell a split story: EPS of -$0.13 beat the -$0.18 estimate, but quarterly revenue collapsed to $258K from $5.9M a year ago. The beat on the loss line gives the bulls a talking point, but the revenue drop is stark. This is a $147M market-cap small-cap biotech running on fumes of product revenue, and the week heading into the print saw short sellers heading for the exits.
Short interest has shed about 22% over the past week, falling to roughly 1.7% of free float — a meaningful unwind after a threefold build over the prior month. The April spike, which took short interest from under 350K shares to nearly 1.4 million by late April, looks like a pre-earnings positioning trade that is now being reversed. The borrow market backs this up: cost to borrow is a negligible 0.80% APR, and availability is sitting at over 400% of short interest — meaning the lending pool has ample supply and there is no squeeze pressure at all. This is not a story about forced covering; it's a story about shorts taking profits after a positioning window closed.
Options positioning reinforces the lack of urgency. The put/call ratio is 0.14, barely a rounding error, and essentially flat against its 20-day average of 0.14. There is no unusual demand for downside protection and no elevated call-buying signalling aggressive upside bets. The 52-week range on the PCR runs from 0.02 to 0.82, which shows that options activity can move dramatically on this name — but right now the market is unusually quiet. The ORTEX short score has drifted down from 48.5 to 42.8 over the past two weeks, a modest easing that mirrors the short interest unwind.
The institutional setup reveals a concentrated ownership structure. GSK Equity Investments holds 15.9% of shares, with Pfizer Venture Investments at 4.1%. Together, pharma strategic investors control a meaningful portion of the register, suggesting the company's antibacterial pipeline retains at least some corporate interest. On the active management side, Two Sigma built a fresh 372K-share position as of year-end 2025, while Renaissance trimmed by 173K and Anson Group cut aggressively — down 979K shares in its last reported filing. Insider activity has been one-way selling: the CFO and COO have made repeated small disposals throughout Q1 and into early May, with the CFO selling 25,240 shares on May 4 at $2.51. Individual transaction sizes are modest — under $120K each — which limits the signal weight, but the consistency of the selling is notable.
Analyst coverage is thin and dated. The most recent changes on record are from early 2025, which is beyond the reliable staleness threshold. HC Wainwright maintained a Buy with a $5.00 target, implying roughly 97% upside to the current $2.54 price — a figure to treat cautiously given coverage has not been updated recently. The formal consensus is a single Hold. The ORTEX EPS surprise factor ranks in just the 1st percentile, meaning the company's historical beat rate sits near the bottom of the universe, which adds context to the Q1 beat — it's the exception, not the rule.
The stock is up 5% on the week heading into the earnings release, with close biotech peers MGNX surging 19% on the day and CRBU adding 5% over the week, while RXRX fell 6.5%. The Q2 earnings event is pencilled in for May 20 per the snapshot data, which is an unusually short gap — worth watching to see whether that date moves. With revenue running well below year-ago levels, the next catalyst is less about whether quarterly numbers improve and more about what the pipeline update reveals regarding SPRO-006 and the company's broader antibacterial franchise.
See the live data behind this article on ORTEX.
Open SPRO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
